Latest news articles

Added 10 days ago Drug news

ASCERTAIN phase III study of ASTX 727 meets primary endpoint in myelodysplastic syndromes or chronic myelomonocytic leukemia

Astex Pharmaceuticals announced top-line results from the ASCERTAIN phase III study evaluating ASTX 727 (cedazuridine and decitabine) fixed-dose combination vs...

Added 1 month ago Drug news

CHMP recommends Doptelet to treat severe thrombocytopenia in adult patients with chronic liver disease

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...

Added 2 months ago Drug news

Celgene and Acceleron Pharma submit BLA for luspatercept for the treatment of myelodysplastic syndromes-associated anemia who have ring sideroblasts

Celgene Corporation and Acceleron Pharma Inc. announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid...

Search all news articles for Neoplasms of unspecified nature or uncertain behaviour
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Guidelines

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines...

Added 3 years ago

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Adult soft tissue and visceral sarcomas (excluding gastrointestinal stromal tumor, GIST) are rare tumors, with an estimated incidence averaging 4–5/100 000/year in Europe.

Added 4 years ago

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, with a median age at diagnosis...

Added 4 years ago

Search all guidelines for Neoplasms of unspecified nature or uncertain behaviour
 

Journal articles

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an allogeneic hematopoietic stem cell transplant (HSCT)...

Added 1 month ago

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.

Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade...

Added 2 months ago

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

The aim of the present retrospective study is to build a comprehensive picture of all alternative REG strategies adopted in daily clinical practice for use in metastatic GIST patients.

Added 10 months ago

Search all journal articles for Neoplasms of unspecified nature or uncertain behaviour
 

Clinical trials

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to IPSS-R very low, low, or intermediate MDS...

Added 11 months ago

Search all clinical trials for Neoplasms of unspecified nature or uncertain behaviour